Zomedica Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	32.03	27.29	25.19	18.93	4.13
Revenue Growth (YoY)	17.39%	8.33%	33.05%	358.02%	-
Cost of Revenue	10.35	8.2	7.87	5.46	1.08
Gross Profit	21.68	19.09	17.32	13.47	3.05
Selling, General & Admin	43.03	46.85	43.17	32.81	22.85
Research & Development	7.17	7.27	5.74	2.58	1.58
Operating Expenses	50.2	54.12	48.91	35.39	24.43
Operating Income	-28.52	-35.03	-31.59	-21.92	-21.37
Interest Expense	-	-	-0.18	-0	-0.01
Interest & Investment Income	2.44	3.97	5.46	2.7	0.36
Currency Exchange Gain (Loss)	-0.01	-0.25	0.03	-0.15	-0.03
Other Non Operating Income (Expenses)	-0.14	0.01	-0.09	-0.01	0.05
EBT Excluding Unusual Items	-26.24	-31.31	-26.38	-19.38	-21
Impairment of Goodwill	-45.56	-16.02	-12.2	-	-
Gain (Loss) on Sale of Investments	-	-	2.17	-	-
Gain (Loss) on Sale of Assets	-0.07	-0.21	0.02	0	-0.25
Asset Writedown	-10.28	-	0.51	-	-
Other Unusual Items	-	-	-	-	0.53
Pretax Income	-82.14	-47.54	-35.86	-19.38	-20.72
Income Tax Expense	-0.28	-0.56	-1.33	-2.37	-2.33
Net Income	-81.86	-46.98	-34.53	-17.02	-18.38
Preferred Dividends & Other Adjustments	-	-	-	-	32.04
Net Income to Common	-81.86	-46.98	-34.53	-17.02	-50.42
Shares Outstanding (Basic)	980	980	980	980	957
Shares Outstanding (Diluted)	980	980	980	980	957
Shares Change (YoY)	-	-	-	2.45%	162.46%
EPS (Basic)	-0.08	-0.05	-0.04	-0.02	-0.05
EPS (Diluted)	-0.08	-0.05	-0.04	-0.02	-0.05
Free Cash Flow	-18.22	-28.84	-27.31	-14.22	-14.42
Free Cash Flow Per Share	-0.02	-0.03	-0.03	-0.01	-0.01
Gross Margin	67.68%	69.95%	68.76%	71.15%	73.89%
Operating Margin	-89.04%	-128.38%	-125.44%	-115.81%	-517.15%
Profit Margin	-255.57%	-172.19%	-137.10%	-89.88%	-1220.01%
Free Cash Flow Margin	-56.87%	-105.71%	-108.45%	-75.12%	-348.97%
EBITDA	-20.57	-27.04	-25.29	-17.88	-20.24
EBITDA Margin	-64.22%	-99.11%	-100.43%	-94.46%	-
D&A For EBITDA	7.95	7.99	6.3	4.04	1.14
EBIT	-28.52	-35.03	-31.59	-21.92	-21.37
EBIT Margin	-89.04%	-128.38%	-125.44%	-115.81%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.